Eldor J, Frankel D Z
Department of Anesthesia, Hadassah Medical Center, Jerusalem, Israel.
Resuscitation. 1989 Oct;18(1):103-10. doi: 10.1016/0300-9572(89)90117-2.
Neostigmine was first used 50 years ago to treat sinus tachycardia and paroxysmal auricular tachycardia. Then there were reports of successful treatment by neostigmine of other forms of supraventricular tachycardias. However, reports of sudden death using neostigmine for reversal of neuromuscular blockade at the end of an operation, which were not properly treated with atropine abandoned the use of neostigmine as an antiarrhythmic drug. Low-dose neostigmine intravenously was used in the treatment of supraventricular tachycardia in three patients described herein. It gave an immediate bradycardic effect in all three patients. The use of a low-dose neostigmine intravenously for an immediate treatment of supraventricular tachycardia is a novel suggestion. It has to be further evaluated and compared to the conventional drugs used like digoxin, verapamil, propranolol or esmolol.
新斯的明于50年前首次用于治疗窦性心动过速和阵发性房性心动过速。随后有报道称新斯的明成功治疗了其他形式的室上性心动过速。然而,关于在手术结束时使用新斯的明逆转神经肌肉阻滞导致猝死且未用阿托品妥善处理的报道,使得新斯的明不再用作抗心律失常药物。本文描述了3例患者静脉注射低剂量新斯的明治疗室上性心动过速。在所有3例患者中均产生了即刻的心动过缓效应。静脉注射低剂量新斯的明即刻治疗室上性心动过速是一个新的建议。它必须进一步评估,并与地高辛、维拉帕米、普萘洛尔或艾司洛尔等传统药物进行比较。